uniQure N.V. (QURE)

5.76 +0.14 (+2.49%) At close: 04:00PM EDT

uniQure N.V.

Paasheuvelweg 25
Amsterdam 1105 BP
Netherlands
31 20 240 6000
https://www.uniqure.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 480

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Matthew Craig Kapusta	CEO & Executive Director	1.02M	N/A	1972
Mr. Christian Klemt	CFO, Principal Financial Officer & GM of Amsterdam Site	575.46k	N/A	1973
Mr. Richard Porter Ph.D.	Chief Business & Scientific Officer	732.17k	N/A	1968
Dr. Jeannette Potts J.D., Ph.D.	Chief Legal & Compliance Officer and Corporate Secretary	635.56k	N/A	1962
Prof. Hugo Katus	Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany	N/A	N/A	N/A
Dr. Amin Abujoub Ph.D.	Chief Technical Operations	N/A	N/A	N/A
Dr. Tamara Tugal Ph.D., MBA	Business Development Director	N/A	N/A	N/A
Ms. Maria E. Cantor	Chief Corporate Affairs Officer	491.12k	N/A	1968
Dr. Walid Abi-Saab M.D.	Chief Medical Officer	N/A	N/A	1965
Eileen Sawyer	Vice President of Global Medical Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Corporate governance

uniQure N.V.’s ISS governance QualityScore as of 18 September 2024 is 3. The pillar scores are Audit: 4; Board: 3; Shareholder rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.